Glucotrack, Inc.

GCTK

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001506983


None

No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $7.8M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	dilution, short runway, thin data not computable: distress, fortress balance sheet
Inputs computable	5 of 14
Graded from	filings received through Mar 30, 2026 227 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026
Last close	$1.36 2026-10-29; market equity $959,147; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 30, 2026

the context otherwise requires, the terms "we", "our", "ours" "us", "Company" and "Glucotrack" refer to Glucotrack, Inc., a Delaware corporation. Company was incorporated on May 18, 2010 under the laws of the State of Delaware.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 6.6						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						
Accruals ratio	(60.2%)	(6.6%)		6.6	801	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

five annual gross margins are required; found 0						
Solvency, sleeve percentile 85.2						
Twelve-month failure probability	not computable	0.08%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	(73.93)	(0.35)		92.7	745	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
interest expense must exceed $100,000						
Current ratio	1.61x	2.95x		77.7	827	2025-12-31
Growth and financing, sleeve percentile 50.4						
Revenue growth, three-year compound	not computable	10.1%				
latest aligned inputs end 2019-12-31; latest annual assets end 2025-12-31						
Free cash flow growth, three-year compound	not computable	11.0%				
four consecutive annual FCF observations are required; found 14						
Reinvestment rate	not computable	37.1%				
one or more required annual facts are missing						
Asset growth, three years	47.6%	2.2%		8.4	695	2025-12-31
Net share issuance, one year	355.9%	2.5%		92.5	628	2026-03-30

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 355.9%
Short runway	cash runway is 0.8 months
Thin data	5 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-10-29 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(74.7%)	(1.9%)	7
Distance from 52-week high	(79.6%)	(27.8%)	8
EBIT to enterprise value	not computable	(1.6%)	
Free cash flow yield	(1,564.4%)	(1.0%)	1
Book value to price	(1.78)	0.27	1
Sales to price	0.21	0.29	41
Composite equity issuance, five years	not computable	20.8%	
Relative strength against the sector, log excess return	(1.54)	(0.19)	7

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Cash, filings, liquidity	
Cash and equivalents	$1.1M
Operating cash flow, four quarters	-$16.2M
Months of runway	0.8
Days since last periodic filing	90 (10-Q received Aug 14, 2026)
Median daily dollar volume, 63 sessions	$198,923

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$19.4M	2025-12-31	2026-03-30	10-K	26-013656
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$15.2M	2025-12-31	2026-03-30	10-K	26-013656
3	assets	us-gaap:Assets	$7.8M	2025-12-31	2026-03-30	10-K	26-013656
4	assets	us-gaap:Assets	$5.9M	2024-12-31	2026-03-30	10-K	26-013656
5	current assets	us-gaap:AssetsCurrent	$7.7M	2025-12-31	2026-03-30	10-K	26-013656
6	current liabilities	us-gaap:LiabilitiesCurrent	$4.8M	2025-12-31	2026-03-30	10-K	26-013656
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$151.8M	2025-12-31	2026-03-30	10-K	26-013656
8	operating income	us-gaap:OperatingIncomeLoss	-$16.1M	2025-12-31	2026-03-30	10-K	26-013656
9	book equity	us-gaap:StockholdersEquity	$2.8M	2025-12-31	2026-03-30	10-K	26-013656
10	liabilities	us-gaap:Liabilities	$5.0M	2025-12-31	2026-03-30	10-K	26-013656
11	operating income	us-gaap:OperatingIncomeLoss	-$14.5M	2024-12-31	2026-03-30	10-K	26-013656
12	interest expense	us-gaap:InterestExpense	$44,000	2024-12-31	2025-03-31	10-K	25-001861
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$208,000	2019-12-31	2021-04-13	10-K	21-008654
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$43,488	2018-12-31	2020-04-14	10-K	20-006370
15	revenue	us-gaap:Revenues	$589,462	2017-12-31	2018-03-30	10-K	18-001056
16	revenue	us-gaap:Revenues	$611,689	2016-12-31	2018-03-30	10-K	18-001056
17	assets	us-gaap:Assets	$4.9M	2023-12-31	2025-03-31	10-K	25-001861
18	assets	us-gaap:Assets	$2.4M	2022-12-31	2024-03-28	10-K	24-011765
19	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,944,279	2026-03-30	2026-03-30	10-K	26-013656
20	shares outstanding	dei:EntityCommonStockSharesOutstanding	25,585,853	2025-03-31	2025-03-31	10-K	25-001861

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.